ARCHIVES

Genentech Reps Not Welcome: Hospitals Urge Drug Maker to Reverse Policy On Supplying Avastin, Rituxan, & Herceptin

This article is from The Cancer Letter archive.

Vol. 40 No. 39 | October 17, 2014

Download PDF Visit The Full Archive

Related Articles

Three NCAB Members Say They Cannot Offer “Strong Endorsement” Of P-4 Trial.

June 15, 2007

Cancer Biomarker Research “Piecemeal and Unorganized,” IOM Report Finds.

April 6, 2007

Samuel Waksal Pleads Guilty To Tax Evasion

March 7, 2003

Search Committee Sends Short List For NCI Director To HHS, White House

April 7, 1995

Arimidex Gets Full Approval For HR+ Early Breast Cancer

September 30, 2005

Letter: Boy Has Little Chance At Cure Without Proven Treatments.

February 11, 2000